• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Lite Strategy Inc.

    2/17/26 8:45:49 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LITS alert in real time by email

    Unavailable

    Get the next $LITS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LITS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LITS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO, CFO and Secretary File Justin J.

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    2/12/26 5:44:48 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Schornstein Alexander sold $946,137 worth of shares (690,611 units at $1.37), decreasing direct ownership by 16% to 3,674,862 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:15:14 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $97,699 worth of shares (70,000 units at $1.40), increasing direct ownership by 233% to 100,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Flynn James P bought $97,699 worth of shares (70,000 units at $1.40), increasing direct ownership by 233% to 100,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $22,777 worth of shares (12,100 units at $1.88), increasing direct ownership by 68% to 30,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    SEC Filings

    View All

    Lite Strategy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    5/13/26 8:35:15 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lite Strategy Inc.

    10-Q - Lite Strategy, Inc. (0001262104) (Filer)

    5/13/26 8:30:40 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    2/17/26 8:50:24 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

    SAN DIEGO, June 19, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or the "Company"), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced its participation in a featured panel at the Litecoin Foundation Summit, taking place June 22-23, 2026 at the Tobacco Theatre in Amsterdam, Netherlands. The Litecoin Foundation Summit is the flagship annual gathering of the Litecoin ecosystem, held this year in collaboration with Dutch Blockchain Week. The two-day event brings together builders, institutional voices, and community members for discussions spanning payments, privacy, and sound money. The panel will feat

    6/19/26 8:30:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Leads Strategic Investment in LitVM

    SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or the "Company"), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced the closing of a $1.0 million lead strategic investment in ZK Innovations Inc., the developer of LitVM, the first zero-knowledge (ZK) Layer 2 platform built on Litecoin. The investment reflects Lite Strategy's belief that increasing Litecoin's utility and functionality can strengthen the network and increase long-term shareholder value. In addition to the investment, Lite Strategy received governance participation rights and the opportunity to acquire a portion of LitV

    6/18/26 8:30:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Reports Fiscal 2026 Third Quarter Results

    SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or the "Company"), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the fiscal 2026 third quarter ended March 31, 2026. Business and Financial Highlights: Active Treasury Management: Successfully continued the Company's covered call option program, generating $0.7 million in net proceeds since October 2025 and further demonstrating Lite Strategy's ability to transform its LTC holdings into a yield-generating reserve asset and differentiate itself from passive investment vehicles.Share Repurchase Program: Deployed

    5/13/26 8:30:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care